Arnaud Bourreille
Arnaud Bourreille is an expert in Gastroenterology at Centre Hospitalier Universitaire de Nantes (France). As of October 2026, ScienceLeadR ranks Arnaud Bourreille in the top 1% of experts worldwide for Crohn Disease, Inflammatory Bowel Diseases and Gastroenteritis. Arnaud Bourreille has authored 291 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 12 of them ongoing. SLR score: 1,289 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Hepatology - Pharmacy - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 291
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study. PMID 42802497 — safety, cohort studies, inflammatory bowel diseases, pharmacology, therapeutics, pharmacokinetics | Aliment Pharmacol Ther | 2026 | 1 |
| Artificial Intelligence-Based Localization of Small Bowel Anatomic Transition Zones in Crohn's Disease Using Capsule Endoscopy. PMID 42344382 — intelligence, crohn disease, colon, capsule endoscopy, capsules, endoscopy, inflammatory bowel diseases, artificial intelligence, pylorus | Endosc Int Open | 2026 | 0 |
| Artificial Intelligence Versus Conventional Scoring for Assessing Small Bowel Capsule Endoscopy Cleanliness in Crohn's Disease. PMID 42262977 — intelligence, crohn disease, capsule endoscopy, capsules, endoscopy, artificial intelligence, gastrointestinal diseases | United European Gastroenterol J | 2026 | 0 |
| The GETAID: over 40 years of academic research in IBD. PMID 42063669 — biomedical research, inflammatory bowel diseases, research, colitis, ulcerative | Ther Adv Gastroenterol | 2026 | 0 |
| Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic era. PMID 41905522 — crohn disease, risk factors, biological therapy | Clin Gastroenterol Hepatol | 2026 | 0 |
Clinical Studies 34
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 15
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease 2026-525922-39-00 — safety, crohn disease | Phase 3 | Not yet recruiting | 2026 |
| Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis 2026-525923-26-00 — colitis, safety, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn s disease 2025-521037-86-00 — safety, crohn disease, maintenance, immune system diseases, immune system | Phase 3 | Recruiting | 2026 |
| Crohn s Head to Head Assessing Risankizumab Versus Guselkumab for One Year 2025-521590-13-00 — safety, crohn disease, therapeutics, head | Phase 3 | Recruiting | 2026 |
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative colitis 2025-521038-27-00 — colitis, safety, maintenance, immune system diseases, immune system, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map